TATVA1,655.00

Tatva Chintan Pharma Chem Limited

· Chemicals
₹ CrorePeersVISHNUJUBLCPLKIRIINDUSFOSECOINDCHEMPLASTSDDEVPLSTIKGUJALKALIYASHOMcap ₹3,871 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
TATVA
FY26
VISHNU
FY26
JUBLCPL
FY26
KIRIINDUS
FY26
Peer
Median
Valuation — at last close
P/E92.05×34.16×24.94×0.56×24.94× +269%
P/B4.95×4.52×6.95×0.49×4.52× +9%
EV/EBITDA42.79×21.32×16.43×1.88×16.43× +160%
Market Cap₹3,871 Cr₹4,862 Cr₹3,198 Cr₹3,150 Cr₹3,198 Cr +21%
Growth
Revenue CAGR 3Y6.09%4.99%-3.87%0.56% +987%
Revenue CAGR 5Y18.85%-8.45%5.20%
Net Income CAGR 3Y-2.58%1.37%273.73%137.55% -102%
Revenue YoY (latest Q)42.95%24.93%18.38%54.54%24.93% +72%
Net Income YoY (latest Q)140.28%23.02%4.49%2768.13%23.02% +509%
Profitability
EBITDA Margin18.42%15.68%10.36%-26.31%10.36% +78%
Net Income Margin8.31%8.84%6.76%663.01%8.84% -6%
Return on Common Equity5.38%13.24%27.80%86.37%27.80% -81%
Return on Capital Employed7.12%14.63%34.81%-4.12%14.63% -51%
Return on Assets4.19%6.81%13.67%79.09%13.67% -69%
Credit & Quality
Total Debt/Equity0.15×0.49×0.06×0.01×0.06× +150%
Interest Coverage19.75×5.50×27.08×-1.37×5.50× +259%
Scale — latest FY
Revenue / Total Income₹506 Cr₹1,610 Cr₹1,891 Cr₹840 Cr₹1,610 Cr -69%
Net Income₹42.1 Cr₹142 Cr₹128 Cr₹5,567 Cr₹142 Cr -70%
Total Assets₹1,004 Cr₹2,088 Cr₹935 Cr₹7,039 Cr₹2,088 Cr -52%
EPS₹17.98₹21.14₹84.64₹941.32₹84.64 -79%
Book Value per Share₹334.2₹159.63₹303.56₹1,073.8₹303.56 +10%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.